secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001171843-26-001340
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing
--------------------------------------------------------------------------------

- Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.
- Cash, cash equivalents and investments $77.8M as of Dec 31, 2025, up from $56.9M; funding expected into Q3 2026.
- Phase 2 B-SUPREME study of pevifoscorvir sodium completed 60 HBeAg- enrollment; topline data expected 2027.
- ALG-170675 ASO advanced to IND-enabling studies with partner Amoytop; Amoytop funds China development.
- James Hassard appointed EVP, Chief Commercial Officer; ALG-055009 preclinical data showed synergistic weight loss with incretins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184326001340/0001171843-26-001340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184326001340/f8k_030426.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer